GoodRx (GDRX) shares surged 50% after partnering with Novo Nordisk. Self-paying patients can access Ozempic and Wegovy pens for $499/month through GoodRx. Stock is up 12% in 2025. Teaming with Novo Nordisk boosts GoodRx in the GLP-1 market. $499/month offerings expand access and drive user growth.

Bank of America analyst warns Novo Nordisk deal isn’t enough reason to buy GoodRx shares. Closures and policy changes may hinder momentum. Analyst maintains “Underperform” rating and $3.40 price target, suggesting over 30% downside. BofA is bearish on GoodRx in 2025.

Consensus rating on GDRX shares is “Moderate Buy” with $5.49 mean target, indicating 5% upside. Bank of America Securities among the more bearish on GoodRx stock in 2025. Wajeeh Khan has no positions in mentioned securities. Information in this article is for informational purposes only.

Read more at Yahoo Finance: GoodRx Is Soaring on a Novo Nordisk Deal. Should You Buy GDRX Stock Here?